**Exploring Temple’s FDA Legacy, Chinese Biotech Innovation, and Novo Nordisk’s Obesity Data – A BioCentury Podcast** The biopharmaceutical industry is...

**Exploring a Unique Collection Addressing Challenges Through Interdisciplinary Approaches** In an increasingly complex and interconnected world, the challenges we face...

# Understanding Supra-Thermal Ions in Inertial Systems: Key Insights and Mechanisms In the realm of plasma physics and inertial confinement...

# Key Medical Breakthroughs and Innovations of 2024 The year 2024 has proven to be a landmark period for medical...

# Top Six Biotech Companies Driving Innovation in India India has emerged as a global hub for biotechnology, leveraging its...

**Lactoferrin Inhibits Hepatocellular Carcinoma Progression by Targeting INTL1 Receptor and Modulating Apoptosis and Cell Cycle Pathways** Hepatocellular carcinoma (HCC) is...

# Dynamic Transcriptomics Reveals Coordinated Transcriptional Regulation of Artemisinin and Phenylpropanoid Biosynthesis Pathways in *Artemisia annua* Under Cold Stress ##...

# Engineering *Escherichia coli* for Optimized Fermentation Conditions in Whole-Cell Catalytic Synthesis of D-Allulose ## Introduction D-Allulose, also known as...

# Production, Purification, and Biological Activity Assessment of Recombinant Tilapia Lake Virus Segment 4 Protein for Vaccine Development ## Introduction...

**Impact of Initial Glucose Levels on Vidal Grape Juice Fermentation Efficiency in Ice Wine Production** Ice wine, a luxurious and...

# Exploring the Role and Impact of Natural Killer Cells [Rebroadcast] Natural Killer (NK) cells are a fascinating and essential...

# Exploring the Role and Impact of Natural Killer Cells The human immune system is a complex and highly coordinated...

**Utilizing Stem Cell Membrane Antigens for Immune System Applications** The field of regenerative medicine and immunotherapy has witnessed remarkable advancements...

**Development of a Fully Automated SIMPLE RPA Microfluidic Chip for In Ovo Sex Determination** The poultry industry is a cornerstone...

**How Biotechnology is Turning Christmas Miracles into Reality** The holiday season is a time of wonder, joy, and the occasional...

**How Biotech Innovations Are Turning Christmas Miracles Into Reality** The holiday season is a time of wonder, joy, and hope—a...

**Exploring CAR T Cells Through a Festive Parody Song on the Nature Podcast** In the ever-evolving world of science communication,...

# CAR T Cells: A Festive Parody Song Celebrated on the *Nature* Podcast In the world of science communication, creativity...

**CAR T Cells: A Festive Parody Song Featured on the Nature Podcast** In the world of science communication, creativity often...

**CAR T Cells Explained: A Festive Parody Song from the Nature Podcast** In the world of cutting-edge medical science, few...

**James Wilson’s GEMMABio Raises $34 Million to Propel Gene Therapy Innovations** In a significant milestone for the field of gene...

**GEMMABio Raises $34 Million Under James Wilson’s Leadership to Propel Gene Therapy Innovations** In a groundbreaking development for the biotechnology...

**FDA Approves Vertex Drug for Treating Cystic Fibrosis: A Breakthrough in Precision Medicine** In a landmark decision that underscores the...

# Optimizing Blood-Brain Barrier Transcytosis: Shorter Linker Enhances TfR-Mediated Transport in Bispecific Antibody RmAb158-scFv8D3 The blood-brain barrier (BBB) is a...

**Key Engineering Factors in Developing Next-Generation Oligonucleotide Therapeutics** Oligonucleotide therapeutics, a rapidly evolving class of drugs, have emerged as a...

**Serum-Free Conditioned Medium Enables Adhesion and Growth of Bovine Myogenic Cells on Uncoated Surfaces** The field of cellular agriculture has...

# Mathematical Modeling of Ligand Inter-Nanocluster Connectivity Using Modularity to Decipher Reversible Stem Cell Regulation Stem cells are the cornerstone...

**Serum-Free Conditioned Culture Medium Enables Adhesion and Growth of Bovine Myogenic Cells on Uncoated Surfaces** The field of cellular agriculture...

EMA agency recommends the withdrawal of Translarna and BlenRep from the market

EMA Agency Recommends the Withdrawal of Translarna and BlenRep from the Market

The European Medicines Agency (EMA) has recently recommended the withdrawal of two drugs, Translarna and BlenRep, from the market due to safety concerns. This decision comes after a thorough evaluation of the risks and benefits associated with these medications.

Translarna, also known as ataluren, is a drug used to treat Duchenne muscular dystrophy (DMD) in patients who have a specific genetic mutation. It works by promoting the production of dystrophin, a protein that is lacking in individuals with DMD. However, recent evidence has raised concerns about the drug’s effectiveness and potential side effects.

The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) conducted a review of available data and concluded that there is insufficient evidence to support the long-term benefits of Translarna in treating DMD. Additionally, the committee found an increased risk of serious side effects, including kidney toxicity and gastrointestinal disorders. As a result, they have recommended the withdrawal of Translarna from the market.

BlenRep, on the other hand, is a medication used to treat multiple myeloma, a type of blood cancer. It belongs to a class of drugs called antibody-drug conjugates, which work by delivering a toxic substance directly to cancer cells. However, recent data has raised concerns about the drug’s safety profile.

The PRAC conducted a review of available data on BlenRep and found an increased risk of serious side effects, including infusion-related reactions, infections, and liver toxicity. The committee concluded that the risks associated with BlenRep outweigh its benefits and have therefore recommended its withdrawal from the market.

It is important to note that these recommendations are not final decisions. The EMA will now seek input from relevant stakeholders, including healthcare professionals and patient organizations, before making a final decision. If the withdrawal is confirmed, it will be up to national authorities in each European Union member state to implement the recommendation.

The EMA’s decision to recommend the withdrawal of Translarna and BlenRep underscores the agency’s commitment to ensuring the safety and efficacy of medications available in the European market. By conducting thorough evaluations and considering all available evidence, the EMA aims to protect patients from potential harm.

Patients who are currently taking Translarna or BlenRep should not stop their treatment without consulting their healthcare provider. Healthcare professionals will be able to provide guidance on alternative treatment options and address any concerns or questions patients may have.

In conclusion, the EMA’s recommendation to withdraw Translarna and BlenRep from the market highlights the importance of ongoing drug safety monitoring. While these medications were initially approved based on available evidence, further evaluation has raised concerns about their effectiveness and potential side effects. The EMA’s decision aims to prioritize patient safety and ensure that only safe and effective treatments are available to those who need them.